Company profile
Established: 1981
Corporate Headquarters: Cincinnati, Ohio
Employees: 3,475 (as of March 31, 2008)
Locations:
North America: Ann Arbor, Michigan; Chicago, Illinois; Cincinnati, Ohio; Cranford, New Jersey; Durham, North Carolina;
Los Angeles, California; Morgantown, West Virginia; Old Lyme, Connecticut; Rockville, Maryland; Wilmington, North Carolina; Canada: Toronto, Ontario;
Europe: Brussels, Belgium; Sofia, Bulgaria; Prague, Czech Republic; Crowthorne, England; Ely, England; Maidenhead,
England; Lyon, France; Paris, France; Munich, Germany; Tel-Aviv, Israel; Milan, Italy; Saronno, Italy; Utrecht, The Netherlands;
Warsaw, Poland; Bucharest, Romania; Moscow, Russia; Edinburgh, Scotland; Glasgow, Scotland; Barcelona, Spain; Madrid, Spain;
Uppsala, Sweden; Asia/Pacific: Melbourne, Australia; Sydney, Australia; New Delhi, India; Singapore, Singapore; and through a joint venture
in Beijing, China; Latin America: Buenos Aires, Argentina; Rio de Janeiro, Brazil; Santiago, Chile; Bogota, Colombia;
Mexico City, Mexico; Lima, Peru. Africa: Johannesburg, South Africa.
Business Overview
Kendle is among the world's leading, global publicly held clinical research organizations. We deliver innovative and robust clinical development solutions-from first-in-human studies through market launch and surveillance-to help the world's biopharmaceutical companies maximize product life cycles and grow market share. Kendle competes and has competitive advantages in four core competencies, including:
- Clinical Development, which provides Phase I-III clinical research services to biopharmaceutical companies across a broad spectrum of therapeutic areas
- Regulatory Affairs, which provides strategic clinical development planning, regulatory submissions, clinical trial regulatory affairs, nonclinical consulting, CMC development and pharmacovigilance/safety services
- Biometrics, which provides clinical data management, biostatistics and eClinical (EDC) services
- Late Phase, which provides Phase IIIB/IV studies; health economics, patient-reported outcomes and outcomes research; product/disease registries and observational studies; and scientific events, education and publication services
Kendle's customer focus, global scale and innovative technology offer a strategic advantage in bringing life-enhancing and life-saving new medicines to market.
Global Scale
Our global clinical development business is focused on five regions - North America, Europe, Asia/Pacific, Latin America and
Africa. Approximately 54 percent of Kendle's workforce is based outside North America, as is 54 percent of our first quarter
revenue. In addition, we have conducted research and provided clinical services in 90 countries.
Therapeutic Expertise
Kendle contributes to the development, approval and life cycle management of innovative therapies for a broad range of medical
conditions. We have more than 25 years of experience in serving customers both large and small and with a diversity of compounds,
which means that our expertise spans every major therapeutic area. We are focused on growing our Phase I-IV clinical development
expertise in the top five therapeutic areas expected to represent nearly 70 percent of drug sales by 2011; cardiology, oncology,
antibiotics and antivirals, central nervous system (CNS) and arthritis/inflammation.1 Oncology and CNS continue to
be among the largest therapeutic areas for Kendle. We continue to see strong growth in sales for programs in these areas and
we expect them to continue to be growth drivers for our business going forward.
Proprietary Software Solutions: TrialWare®
Kendle's proprietary suite of software products, TrialWare®, enables clinical trial data to be processed faster
through automated workflow, parallel processing and standardization. The TrialWare® family of technology includes
TrialBase®, our database management system; TrialWatch®, our global project management information system;
TriaLine®, our interactive voice response patient randomization system; TrialWeb®, our Web-based communications
and information sharing tool; TriAlert®, our coding enhancement feature, and TrialMD®, our investigator feasibility
and information management system.
1. Source: S.G. Cowen, March 2007
|
